A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Phase of Trial: Phase I/II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seattle Genetics
- 12 Apr 2018 Status changed from active, no longer recruiting to completed.
- 19 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology